Technical Analysis for BYSI - BeyondSpring, Inc.

Grade Last Price % Change Price Change
B 2.23 1.13% 0.03
BYSI closed up 1.13 percent on Friday, November 1, 2024, on 38 percent of normal volume. It was able to find support at its 50 day moving average. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Flat

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Crossed Above 200 DMA Bullish 1.13%
Crossed Above 50 DMA Bullish 1.13%
Narrow Range Bar Range Contraction 1.13%
Oversold Stochastic Weakness 1.13%
Fell Below 200 DMA Bearish 2.76%

   Recent Intraday Alerts

Alert Time
Outside Day about 21 hours ago
Fell Below 200 DMA about 21 hours ago
Fell Below 50 DMA about 21 hours ago
Fell Below Previous Day's Low about 21 hours ago
Down 2 % about 21 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BeyondSpring, Inc. Description

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Cancer Treatment Chemotherapy Antineoplastic Drugs Small Cell Lung Cancer Cancer Therapies Organic Chemistry NSCLC Protein Kinase Advanced Non Small Cell Lung Cancer Buparlisib Docetaxel Neutropenia

Is BYSI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.0
52 Week Low 0.7777
Average Volume 23,418
200-Day Moving Average 2.19
50-Day Moving Average 2.21
20-Day Moving Average 2.32
10-Day Moving Average 2.22
Average True Range 0.13
RSI (14) 47.92
ADX 28.09
+DI 20.45
-DI 14.74
Chandelier Exit (Long, 3 ATRs) 2.13
Chandelier Exit (Short, 3 ATRs) 2.55
Upper Bollinger Bands 2.54
Lower Bollinger Band 2.10
Percent B (%b) 0.29
BandWidth 18.62
MACD Line -0.01
MACD Signal Line 0.01
MACD Histogram -0.0245
Fundamentals Value
Market Cap 87 Million
Num Shares 39 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -3.14
Price-to-Sales 35.99
Price-to-Book 5.38
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.37
Resistance 3 (R3) 2.36 2.30 2.34
Resistance 2 (R2) 2.30 2.27 2.31 2.33
Resistance 1 (R1) 2.27 2.25 2.29 2.28 2.33
Pivot Point 2.21 2.21 2.22 2.22 2.21
Support 1 (S1) 2.18 2.18 2.20 2.19 2.13
Support 2 (S2) 2.12 2.16 2.13 2.13
Support 3 (S3) 2.09 2.12 2.12
Support 4 (S4) 2.10